Experience with Levofloxacin in a Critical Pathway for the Treatment of Community-Acquired Pneumonia

Publisher： Karger

E-ISSN： 1421-9794|50|1|11-15

ISSN： 0009-3157

Source： Chemotherapy, Vol.50, Iss.1, 2004-08, pp. : 11-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Community-Acquired Pneumonia

By  

Chemotherapy, Vol. 46, Iss. 1, 2000-05 ,pp. : 24-31

Karger

Access to resources Recommend Favorite

Optimal Treatment Strategies for Community-Acquired Pneumonia: Non-Responders to Conventional Regimens

By  

Chemotherapy, Vol. 47, Iss. 4, 2001-09 ,pp. : 11-18

Karger

Access to resources Recommend Favorite

Cefuroxime for Empiric Treatment of Community-Acquired Pneumococcal Pneumonia: Is There a Generation Gap?

By  

Chemotherapy, Vol. 55, Iss. 2, 2009-01 ,pp. : 97-104

Karger

Access to resources Recommend Favorite

Biomarkers in Pediatric Community-Acquired Pneumonia

By Principi Nicola   Esposito Susanna  

International Journal of Molecular Sciences, Vol. 18, Iss. 2, 2017-02 ,pp. : 447-447

MDPI

Access to resources Recommend Favorite

Solutions for Difficult Diagnostic Cases of Community-Acquired Pneumonia

By  

Chemotherapy, Vol. 47, Iss. 4, 2001-09 ,pp. : 3-10

Karger

Access to resources Recommend Favorite